Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monsenso ASOCSE:MONSO -3.87%27 EV-to-EBIT is -2.86 as of Aug. 02, 2026. GuruFocus rates OCSE:MONSO with a GF Score™ of 27/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Monsenso AS ranks worse than 212314.01% on this metric.
The historical rank and industry rank for Monsenso AS's EV-to-EBIT or its related term are showing as below:
OCSE:MONSO'
s EV-to-EBIT Range Over the Past 10 Years
Min: -25.27 Med: -1.58 Max: 943.48
Current: -2.85
During the past 9 years, the highest EV-to-EBIT of Monsenso AS was 943.48. The lowest was -25.27. And the median was -1.58.
OCSE:MONSO's EV-to-EBIT is ranked worse than 100% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs OCSE:MONSO: -2.85
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Monsenso AS's Enterprise Value for the quarter that ended in Dec. 2025 was kr11.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monsenso AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-7.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monsenso AS EV-to-EBIT Related Terms
Monsenso AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Monsenso AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, HQY: EV-to-EBIT Comparison
For the Health Information Services subindustry, Monsenso AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Monsenso AS's EV-to-EBIT falls into.
Monsenso AS's current Enterprise Value is kr21.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monsenso AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-7.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monsenso AS (OCSE:MONSO) has a EV-to-EBIT of -2.86 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Monsenso AS and its competitors. According to the industry distribution chart, Monsenso AS ranks #999999 out of 471 companies in the Healthcare Providers & Services industry.
Is Monsenso AS's EV-to-EBIT too high?
Monsenso AS's current EV-to-EBIT is -2.86. Based on the distribution chart, Monsenso AS ranks #999999 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Monsenso AS has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #999999 out of 471 companies for EV-to-EBIT. This places Monsenso AS in the lower half of its industry. The industry median EV-to-EBIT is 15.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current EV-to-EBIT is -2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.30 — trading 98.7% above its estimated fair value. The current EV-to-EBIT is -2.86. Monsenso AS's overall GF Score™ is 27/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current EV-to-EBIT is -2.86 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.30 is trading 98.7% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
EV-to-EBIT: -2.86
GF Value™: kr0.15 vs. price of kr0.30 (98.7% above fair value)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
27GF Score
Get the complete analysis for OCSE:MONSO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
